CAMBRIDGE, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX - News), a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases, today reported unaudited financial results for the second quarter ended June 30, 2007. At June 30, 2007, Idenix's cash, cash equivalents and marketable securities totaled approximately $160 million with no debt.
